Incorporating biomarkers into clinical drug trials in Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 3, Issue 3, 2001, Pages 287-292

  Growdon, J H ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; CEVIMELINE; DONEPEZIL; HYDROXYCHLOROQUINE; PHYSOSTIGMINE; TACRINE; TAU PROTEIN;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; BRAIN PERFUSION; CLINICAL RESEARCH; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DRUG MECHANISM; ENTORHINAL CORTEX; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR GENETICS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHARMACOGENETICS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 0034972863     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2001-3303     Document Type: Article

References (29)

1. Treatment of Alzheimer's disease
2. A controlled trial of selegiline, α tocopherol, or both as treatment of Alzheimer's disease
3. Molecular genetics of Alzheimer's disease
4. Association of apolipoprotein E allele ε4 with late-onset familial and sporadic Alzheimer's disease
5. Clinical and pathological correlates of apolipoprotein E e/4 in Alzheimer's disease
6. Apolipoprotein E genotype does not influence rates of cognitive decline in Alzheimer's disease
7. Utility of APOE genotype in the diagnosis of Alzheimer's disease
8. Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease
9. Plasma amyloid β-peptide 1-42 and incipient Alzheimer's disease
10. 42 in the cerebrospinal fluid of patients with Alzheimer's disease
11. (1-42) and tau levels in CSF
12. To tap or not to tap: Cerebrospinal fluid biomarkers in Alzheimer's disease
13. Measurement of medial temporal lobe atrophy in diagnosis of Alzheimer's disease
14. Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease
15. Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease
16. Functional neuroimaging in dementia
17. Preclinical prediction of Alzheimer's disease using SPECT
18. Surrogate end points in clinical trials: Are we being misled?
19. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease
20. Serial magnetic resonance imaging of cerebral atrophy in preclinical Alzheimer's disease
21. Correlation between rates of brain atrophy and cognitive decline in AD
22. Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease
23. Apolipoprotein ε4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease
24. Donepezil therapy in clinical practice
25. Neurotrophic and neurotoxic effects of amyloid beta protein: Reversal by tachykinin neuropeptides
26. The selective muscarinic MI agonist AF102B decreases levels of total Aβ in CSF of patients with Alzheimer's disease
27. Activation of protein kinase C inhibits cellular production of the amyloid β-protein
28. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease
29. Consensus report of the working group on: Molecular and biochemical markers of Alzheimer's disease